TABLE 3.
Patients' treatment regimens and outcomes
| All patient s (n = 40) | Moderate pneumonia (n = 33) | Severe pneumonia (n = 7) | P‐value | |
|---|---|---|---|---|
| Treatment modalities and outcomes | ||||
| Withdrawal of IS agent (n, %) | ||||
| Calcineurin inhibitors | 11 (27.5%) | 7 (21.2%) | 4 (57.1%) | .075 |
| Antimetabolites | 40 (100%) | 33 (100%) | 7 (100%) | 1 |
| mTOR inhibitors | 4 (10%) | 3 (9.1%) | 1 (14.3%) | 1 |
| Treatment of infection (n, %) | ||||
| Favipiravir | 18 (45%) | 12 (36.4%) | 6 (85.7%) | .024 |
| Anti‐cytokine agents (n, %) | ||||
| Tocilizumab | 5 (12.5%) | 2 (6.1%) | 3 (42.9%) | .024 |
| Anakinra | 3 (7.5%) | 3 (9.1%) | 0 | |
| Antibiotics (n, %) | 24 (60%) | 21 (63.6%) | 3 (42.9%) | .273 |
| Ventilation devices (n, %) | ||||
| Nasal cannula | 37 (92.5%) | 30 (90.9%) | 7 (100%) | 0.407 |
| Non‐invasive ventilation | 4 (10%) | 1 (3%) | 3 (42.9%) | .013 |
| Mechanical ventilation | 6 (15%) | 0 | 6 (85.7%) | <.001 |
| Follow‐up in intensive care unit | 7 (17.5%) | 0 | 7 (100%) | <.001 |
| Number of patient fatalities (n, %) | 5 (12.5%) | 0 | 5 (71.4%) | <.001 |
P‐values compared moderate pneumonia and severe pneumonia, obtained from the chi‐square test, Fisher's exact test, or Mann‐Whitney U test.
P‐values in bold showed statistically significant differences.
Abbreviations: IS, immunosuppression; mTOR, mammalian target of rapamycin.